Sign in Subscribe

crc-research

A collection of 943 issues

Korean study finds early-onset CRC not more advanced at diagnosis

Skip to content The CRC Digest Korean study finds early-onset CRC not more advanced at diagnosis Among 20,941 patients, 9.8% had early-onset CRC, with stage distribution and tumor differentiation comparable to late-onset disease, though younger patients more frequently received multimodality treatment. (BMC Cancer) This content is informational only

Circulating tumor DNA detects recurrence months before imaging

Skip to content The CRC Digest ◇ RESEARCH Circulating tumor DNA detects recurrence months before imaging A review of 94 publications found that postoperative ctDNA positivity was consistently associated with increased recurrence risk and poorer survival, with serial monitoring identifying molecular recurrence approximately 2.5 to 11.5 months before conventional

Combining FIT with risk factors improves colonoscopy efficiency

Skip to content The CRC Digest ▪ SCREENING Combining FIT with risk factors improves colonoscopy efficiency A systematic review of 19 studies found that adding risk factors such as age, sex, smoking, and fecal hemoglobin levels to fecal immunochemical testing modestly improved the yield and efficiency of colonoscopy for advanced colorectal

Early-onset colorectal cancer in Korea shows lower mortality than late-onset disease

Skip to content The CRC Digest ◆ TRIAL DATA Early-onset colorectal cancer in Korea shows lower mortality than late-onset disease A nationwide study of 20,941 patients found that early-onset CRC (diagnosed before age 50) was associated with lower overall mortality, cancer-specific mortality, and non-cancer mortality compared to late-onset disease, with

CRC Research Update — October 25, 2026

Today's colorectal cancer research highlights

Molecular profiling study identifies clinicopathological factors linked to dMMR/MSI-H status

Skip to content The CRC Digest Molecular profiling study identifies clinicopathological factors linked to dMMR/MSI-H status In 272 resected colorectal cancers, dMMR/MSI-H was present in 9.6% of tumors and independently associated with younger age, proximal tumor location, and poor differentiation. (Clinical Therapeutics) This content is informational only

Large cohort study maps RAS-pathway mutation patterns in 1,243 colorectal cancer samples

Skip to content The CRC Digest ◇ RESEARCH Large cohort study maps RAS-pathway mutation patterns in 1,243 colorectal cancer samples Whole-exome sequencing revealed KRAS mutations in 35.3% of tumors, BRAF V600E in 6.8%, and PIK3CA in 17.8%, with KRAS-PIK3CA co-mutations occurring in 10.1% overall; RAS-mutant tumors

Simplified 14-day trifluridine-tipiracil schedule shows non-inferior survival in refractory metastatic colorectal cancer

Skip to content The CRC Digest ▸ TREATMENT Simplified 14-day trifluridine-tipiracil schedule shows non-inferior survival in refractory metastatic colorectal cancer The phase III PRABITAS trial in Japan randomized 970 patients and found that a 14-day schedule of trifluridine-tipiracil plus bevacizumab was non-inferior to the conventional 28-day schedule for overall survival, potentially

Final CheckMate 8HW results show survival benefit with nivolumab plus ipilimumab in MSI-H/dMMR metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Final CheckMate 8HW results show survival benefit with nivolumab plus ipilimumab in MSI-H/dMMR metastatic colorectal cancer At 68 months median follow-up, the phase III trial demonstrated significant overall survival benefit with nivolumab plus ipilimumab versus nivolumab alone across all treatment lines

FDA grants accelerated approval for dostarlimab in locally advanced rectal cancer with dMMR tumors

Skip to content The CRC Digest ● REGULATORY FDA grants accelerated approval for dostarlimab in locally advanced rectal cancer with dMMR tumors The immunotherapy Jemperli (dostarlimab-gxly) received accelerated approval for previously untreated stage II or III locally advanced rectal cancer with mismatch repair deficient tumors, potentially allowing some patients to avoid